In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales... Show more
On July 09, 2025, the Stochastic Oscillator for GSK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in of 329 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 233 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for GSK moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GSK turned negative on June 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
GSK moved below its 50-day moving average on July 11, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GSK crossed bearishly below the 50-day moving average on July 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GSK broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.144) is normal, around the industry mean (5.632). P/E Ratio (14.012) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (1.126) is also within normal values, averaging (3.004). Dividend Yield (0.035) settles around the average of (0.161) among similar stocks. P/S Ratio (2.277) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GSK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GSK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
COMT | 26.48 | 0.28 | +1.07% |
iShares GSCI Cmd Dyn Roll Stgy ETF | |||
XES | 68.88 | 0.18 | +0.26% |
SPDR® S&P Oil & Gas Equipment&Svcs ETF | |||
ALTY | 11.63 | N/A | N/A |
Global X Alternative Income ETF | |||
TDEC | 22.11 | -0.03 | -0.14% |
FT Vest Emerging Mkts Buffr ETF - Dec | |||
IJJ | 127.50 | -0.93 | -0.72% |
iShares S&P Mid-Cap 400 Value ETF |
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.